key: cord-0919821-r7iiw6hd authors: Purut, Yunus Emre; Giray, Burak; Gurbuz, Esra title: Effect of the coronavirus pandemic on tumor markers date: 2021-06-12 journal: J Med Virol DOI: 10.1002/jmv.27057 sha: 1a064d46f0d3b2ead4fce3685f70a3f27d008522 doc_id: 919821 cord_uid: r7iiw6hd The new type of coronavirus could cause severe acute respiratory syndrome and injuries in other systems as well. Multiple organ damage can occur rapidly in patients infected with coronavirus disease 2019 (COVID‐19). Previous studies have shown that many laboratory biomarkers were not within the normal ranges in COVID‐19 patients. We aimed to summarize laboratory parameters and the tumor markers in COVID‐19 patients. This is a retrospective cohort study conducted on 53 women between the ages of 19–85 years infected with COVID‐19 at a training and research hospital between May 2020 and August 2020. Of the 53 women, 16 (30.2%) had leukopenia. The mean C‐reactive protein level was 18.42 ± 59.33 mg/L. The mean procalcitonin level was 0.1 ± 0.21 µg/L. The liver function tests were within normal limits. The mean creatinine level was 0.58 ± 0.37 mg/dl. Elevated levels of α‐fetoprotein (AFP) in 1 patient, elevated levels of carcinoembryonic antigen (CEA) in 2 patients, elevated levels of cancer antigen 125 (CA125) in 4 patients, elevated levels of CA19‐9 in 2 patients, and elevated levels of CA15‐3 in 2 patients were detected. One of 4 patients who were taken to the intensive care unit had elevated levels of AFP. In addition, 2 of 4 patients who were taken to the intensive care unit had elevated levels of CA125 and CA15‐3. Except for AFP, levels of all tumor markers of the patient who died were high. We found that COVID‐19 had no effect on tumor markers (CA125, CA19‐9, CA15‐3, AFP, and CEA). Previous studies have shown that many laboratory biomarkers were not within the normal ranges in COVID-19 patients. [1] [2] [3] Some of the cancer biomarkers including carbohydrate antigens have shown an elevation in various inflammatory conditions. 4, 5 In this study, we aimed to summarize laboratory parameters and the tumor markers, including α-fetoprotein (AFP), cancer antigen 125 (CA125), carbohydrate antigen 15-3 (CA15-3), carbohydrate antigen 19-9 (CA19-9), and carcinoembryonic antigen (CEA), among COVID-19 patients. This is a retrospective cohort study conducted on 53 women between the ages of 19-85 years infected with COVID-19 at a training and research hospital between May 2020 and August 2020. Data were recorded and collected from the joint electronic medical database system that included examination notes, clinical and laboratory parameters. There was no disease in the patients except COVID-19. Patients with cancer diagnoses were excluded. The patients' laboratory parameters including age, white blood cell (WBC), neutrophil, lymphocyte, platelet, hemoglobin, C-reactive protein (CRP), d-dimer, lactate, fibrinogen, procalcitonin, troponin, ferritin, lactate dehydrogenase (LDH), alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine, AFP, CA125, CA15-3, CA19-9, and CEA levels were recorded. The patients or relatives gave informed and voluntary consent to the publication of their clinical data and they agreed to participate in this study. The present study included 53 women with COVID-19. The mean age of the women infected with COVID-19 was 42.49 ± 20.31 years. All laboratory parameters of the patients are shown in Table 1 As we know CRP is a significant factor that correlates with the severity of the COVID-19 cases. 6 Our study unveils that a positive correlation between CRP and a series of cancer biomarkers can inform us about an acute pathophysiological injury in COVID-19. Positive correlations between CRP and CEA or CA biomarkers have been found in other diseases such as gastric and colon cancer and number increased in groups, we could determine and divide the patients accordingly into mild, severe and critical groups. Third, we can add other cancer biomarkers to our study and it will be more comprehensive. Fourth, a long-term follow-up is needed to determine if elevated cancer biomarkers in patients are transient or long-term as a risk of tumorigenesis. And the fifth and last limitation is not all routine laboratory tests have been included, as other markers are also valuable in COVID-19, such as coagulation and chemistry markers. As gynecologist oncologists, we tried to reveal a deeper understanding of the interaction between the immune system and cancer biomarkers developed parallel in patients with COVID-19. We found that COVID-19 had no effect on tumor markers (CA125, CA19-9, CA15-3, AFP, and CEA). The authors declare that there are no conflicts of interest. The peer review history for this article is available at https://publons. com/publon/10.1002/jmv.27057. Data are available on request from the authors. Yunus Emre Purut http://orcid.org/0000-0001-5779-3847 Burak Giray http://orcid.org/0000-0002-3832-6634 Esra Gurbuz http://orcid.org/0000-0002-3123-0963 Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors Usefulness of biological markers in the early prediction of corona virus disease-2019 severity Comparison of tumor markers and inflammatory biomarkers in chronic obstructive pulmonary disease (COPD) exacerbations Prognostic value of carcinoembryonic antigen on outcome in patients with coronavirus disease 2019 Elevations of serum cancer biomarkers correlate with severity of COVID-19 Effect of cigarette smoking, pulmonary inflammation, and lung disease on concentrations of carcinoembryonic antigen in serum and secretions The increase of carcinoembryonic antigen (CEA), high-sensitivity C-reactive protein, and neutrophil/lymphocyte ratio in Parkinson's disease Significance of correlation between levels of carcinoembryonic antigen and carbohydrate antigen 19-9, carcinoembryonic antigen and C-reactive protein, carcinoembryonic antigen and alpha-1 antitrypsin in gastric and colon cancer patients Serum amyloid A is a biomarker of severe coronavirus disease and poor prognosis Transient rise in CA 125 in a woman with ovarian carcinoma and COVID-19 infection Using IL-2R/lymphocyte for predicting the clinical progression of patients with COVID-19 Tumor biomarkers predict clinical outcome of COVID-19 patients China Medical Treatment Expert Group for COVID-19. Clinical characteristics of coronavirus disease 2019 in China Effect of the coronavirus pandemic on tumor markers